Search results
Results From The WOW.Com Content Network
Imfinzi clocked $4.24 billion in sales in 2023, and is a blockbuster medicine in AstraZeneca's key oncology portfolio, which makes up more than 20% of its total revenues.
June 25, 2024 at 3:54 AM. (Reuters) -AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type ...
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall ...
Rank Drug Main indication Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban
Prudential's bid of $26.5 billion in stock was reduced to just over $20 billion when Prudential's shares plummeted after the announcement. AIG then stepped in and offered $23 billion which was accepted by American General. 93 2017 PPG Industries: Akzo Nobel: 26.1 32.4 Akzo rejected the unsolicited offer, claiming the revised offer was still too ...
AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not ...
(Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...
June 18, 2024 at 9:19 AM. Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment. AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S ...